Analyst firms · H.C. Wainwright · BLCO
H.C. Wainwright BLCO price target and rating history
Bausch + Lomb Corporation (BLCO) · Health Care
H.C. Wainwright rates Bausch + Lomb Corporation (BLCO) Neutral with a $22 price target, as of its latest action on Nov 2, 2026. It has published 3 rating actions on BLCO since September 2022, including 0 upgrades and 1 downgrade. Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. H.C. Wainwright's $22 is 5% above that.
- Current rating
- Neutral
- Price target
- $22
- Median target, all firms
- $21
- Actions on BLCO
- 3
H.C. Wainwright price target on BLCO
Every H.C. Wainwright rating on BLCO
- Nov 2, 2026
- May 2, 2025
- Sep 12, 2022
How other firms rate BLCO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | $22 | Nov 2, 2026 |
| Barclays | Overweight | $24 | Oct 7, 2026 |
| Leerink Partners | Outperform | $24 | Sep 9, 2026 |
| UBS | Buy | $21 | Jul 28, 2026 |
| Evercore ISI | In-line | $18 | Jan 5, 2026 |
| Citigroup | Buy | $20 | Dec 11, 2025 |
| Morgan Stanley | Overweight | $21 | Dec 2, 2025 |
Questions about H.C. Wainwright and BLCO
- What is H.C. Wainwright's price target for BLCO?
- H.C. Wainwright's latest stated price target for Bausch + Lomb Corporation (BLCO) is $22, from its action on Nov 2, 2026.
- What is H.C. Wainwright's rating on BLCO?
- H.C. Wainwright rates BLCO Neutral, a neutral rating, as of Nov 2, 2026.
- When did H.C. Wainwright last change its view on BLCO?
- On Nov 2, 2026, H.C. Wainwright downgrades to Neutral from Buy, price target $22.
- How does H.C. Wainwright's BLCO target compare with other analysts?
- Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. H.C. Wainwright's $22 is 5% above that.
More BLCO rating histories
All H.C. Wainwright ratingsBLCO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.